Endo buying NuPathe for $105m to launch Zecuity in 2014
This article was originally published in Scrip
Endo Health Solutions will pay $105m in cash for NuPathe and plans to launch the transdermal migraine drug Zecuity during the first half of 2014.
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.